Xylazine Was the Adulterant Everyone Learned to Test For. Medetomidine Is 300 Times Stronger, and the Government Just Defunded the Strips That Catch It

Ask anyone who’s used fentanyl in the last three years what “tranq” means and you won’t get a blank stare. Xylazine — a veterinary sedative that turned up in the fentanyl supply and started leaving people with wounds that wouldn’t heal — became public enough to get its own local news segments, its own wound-care protocols, its own test strips sold next to the fentanyl ones at syringe exchanges. That was the horror everyone learned to name.

The drug that’s actually taking over right now doesn’t have a nickname yet, and the strip that would tell you it’s there just lost its federal funding.

It’s called medetomidine, and outside of a veterinary clinic — where it’s used, like xylazine, to sedate large animals for exams and surgery — almost nobody had heard of it before it started showing up laced into fentanyl in 2022. Chemically, it’s a cousin of xylazine: both are alpha-2 adrenergic agonists, a class of drugs that binds to receptors in the brain and body that dial down the nervous system’s “go” signals. That’s the plain-language version of the mechanism: it’s a sedative that slows your heart rate, drops your blood pressure, and depresses breathing, layered on top of an opioid that already does all three. The difference is potency. Researchers at Public Health Scotland and the Johns Hopkins Center for Mental Health and Addiction Policy put medetomidine at somewhere between 100 and 300 times more potent than xylazine, gram for gram. And naloxone — the drug that reverses an opioid overdose — does nothing for it, exactly as it does nothing for xylazine, because neither one is an opioid. It just makes the opioid on board that much harder to reverse.

From a Philadelphia curiosity to a national pattern in eighteen months

Medetomidine sits inside the broader novel and emerging substance class Rize tracks precisely because it doesn’t fit the categories everyone already has a protocol for — it’s neither a classic opioid nor a classic sedative-of-abuse, and that in-between status is exactly why it moved so fast.

The numbers describe a drug that went from noise to signal fast. National forensic lab data tracked by Johns Hopkins shows medetomidine detections climbing from 247 reports in 2023 to 2,616 in 2024 — better than a tenfold jump — and then to roughly 8,233 reports in 2025. That’s not a localized blip; it’s a curve. The Baltimore City Health Department has been tracking it as a sustained regional threat rather than a one-time contamination event, and Public Health Scotland’s alert — issued for a UK audience but citing the same American surveillance data — treats it as the pattern to watch, not the exception.

The clinical picture backs up the lab data. Johns Hopkins researchers documented 165 patients hospitalized across three Philadelphia health systems between September 2024 and January 2025 for fentanyl withdrawal complicated by medetomidine — and the complication is the part worth sitting with. These patients weren’t going through ordinary opioid withdrawal. They were showing severe autonomic dysfunction: blood pressure and heart rate swinging wildly instead of settling, the body’s regulatory system thrown into chaos in a way that standard xylazine-withdrawal protocols didn’t fix, but that responded to dexmedetomidine, a medically supervised cousin of the same drug family used deliberately, in a hospital, under monitoring. In plain terms: the same chemical family that’s poisoning people on the street is also the treatment that stabilizes them once they’re in a hospital bed — which tells you how narrow the margin between “sedative” and “crisis” really is here, and how much that margin depends on where you are and who’s watching when it happens.

A three-adulterant week: medetomidine, tianeptine, and 7-OH kratom, all fighting the same clock

Medetomidine isn’t showing up in isolation. This is a category — call it “novel and emerging” because that’s the honest, unglamorous truth of it — and right now three separate members of it are moving through federal scheduling processes at once. The DEA proposed a permanent Schedule I ban on tianeptine — an antidepressant abroad, an opioid-receptor agonist at the high doses people take it recreationally, nicknamed “gas station heroin” for where it’s sold — on July 8; public comments close August 7. Poison-control calls involving tianeptine rose from 4 in 2013 to roughly 350 in 2024. Separately, the DEA moved on July 1 to temporarily schedule high-concentration 7-hydroxymitragynine (7-OH), a manufactured, concentrated derivative of kratom’s natural compounds, sold in gas-station shots and vapes — while explicitly carving out an exemption for the trace amounts of 7-OH that occur naturally in whole-leaf kratom botanicals. That order can’t take effect before August 5. And nitazenes — a family of synthetic opioids STAT News has tracked rising from 27 confirmed deaths in 2020 to 409 in 2024 — remain a live threat that the DEA has been scheduling compound by compound, one novel analog at a time, since 2020.

Poison-control calls involving tianeptine rose from 4 in 2013 to roughly 350 in 2024.

If that reads like alphabet soup, here’s the throughline: every one of these substances exists in a gap. A legal gap, in tianeptine’s case, where a drug sold as a supplement slipped past the regulatory system built for medications. A definitional gap, in 7-OH’s case, where “kratom” as a natural botanical and “concentrated 7-OH” as a manufactured extract are being treated, correctly, as different animals by regulators — but not yet by most of the public, or most retailers. And a detection gap, in medetomidine’s case, because the only tool that reliably tells someone what’s actually in their bag before they use it is a test strip, and test strips work by testing for a specific known compound. New compound, no strip, no warning.

The history that makes this predictable, not surprising

This is not the first time regulators have chased a moving chemical target while people died in the gap between “we noticed” and “we scheduled it.” In the 1980s and ’90s, “designer drugs” — chemists tweaking a banned molecule’s structure just enough to dodge the Controlled Substances Act’s specific listing — forced Congress to pass the Federal Analogue Act in 1986, an attempt to ban entire chemical families instead of playing whack-a-mole one molecule at a time. It worked, unevenly, for a while. Then fentanyl analogs did it again in the 2010s, and now medetomidine, tianeptine, and 7-OH are doing it a third time, in three different corners of the supply at once. The lesson every cycle keeps re-teaching is the same one: scheduling a substance stops its legal sale; it does not, on its own, stop demand, and it does not retroactively protect the people who were already using before anyone in Washington had heard the compound’s name. Detection tools — test strips, drug-checking services, wastewater surveillance — are the only part of the system that can move as fast as the chemistry does, because they don’t require knowing a substance is dangerous in advance. They require only knowing it’s there.

Which is exactly the capability the government chose to defund. In April, SAMHSA told its grantees that federal funds could no longer be spent on fentanyl, xylazine, or medetomidine test strips — the precise tools that would let someone check for the drug this piece is about, at the exact moment its national numbers are climbing fastest.

If you use, here’s what still works

This is the same detection gap Rize flagged in last month’s harm-reduction coverage of the SAMHSA test-strip funding letter — it hasn’t closed, and this week’s data says it’s getting wider, not narrower.

You cannot smell, taste, or eyeball your way to knowing whether medetomidine is in what you have. Test strips for it exist and some harm-reduction organizations and syringe service programs still stock them even without federal grant dollars behind the purchase — call ahead and ask. Naloxone remains free, legal, and federally funded everywhere in the country, and it is still worth carrying and using immediately if someone is unresponsive, even when you suspect medetomidine is involved, because most street supply is mixed and the fentanyl in it will still respond. Using around someone else, or with a way to call for help, remains the single biggest factor in whether a bad reaction turns fatal. None of that changed this month. What changed is that the system that’s supposed to help you know what you’re using just got a little less help from Washington — which makes the harm-reduction workers still handing out strips out of their own budgets this month worth more, not less, than they were a year ago.